RESUMEN
BACKGROUND: Recent studies suggest that enoxaparin may have therapeutic effects on oral squamous cell carcinoma. We aimed to assess this effect utilizing xenograft mouse model through evaluations of proliferation and angiogenesis markers at the RNA and protein levels. METHODS: Mice were divided into enoxaparin treatment (n = 4), positive control (n = 4) and negative control (n = 3) groups. Immunohistochemical analyses were performed utilizing Bcl-2, Bax and Ki-67 antibodies. Expression levels of proliferation and apoptosis related genes were calculated utilizing qRT-PCR. Time-dependent proliferation assays were performed in OSC-19 and HEK293 cell-lines. RESULTS: Bax antibody showed positive staining in the cytoplasm and nuclei of tumor cells, while Bcl-2 antibody displayed staining only in the cytoplasm. A proliferation index of 15%-20% was found in all groups with the Ki-67 marker indicating no metastasis. Enoxaparin treatment caused decrease in BCL2, BAX and CCNB1 genes' expressions. Compared to HEK293, proliferation assays demonstrated higher division rates in OSC-19 with a significant decrease in viability after 96 h. CONCLUSION: Reduced BCL-2 expression indicates a regression of tumor growth, but reduced BAX expression is not correlated with increased apoptosis. Despite the aggressive nature of OSC-19, our results showed a low cell viability with a high division rate when compared with the control HEK293. This paralleled our in vivo findings that showed absence of lymph node metastasis across all mice groups. This discrepancy with the literature suggests that further investigations of the underlying mechanisms and protein-level analyses are needed to draw definitive conclusions about the effect of enoxaparin on OSC-19 behavior.
Asunto(s)
Carcinoma de Células Escamosas , Proliferación Celular , Enoxaparina , Neoplasias de la Boca , Animales , Enoxaparina/uso terapéutico , Enoxaparina/farmacología , Neoplasias de la Boca/tratamiento farmacológico , Neoplasias de la Boca/patología , Proyectos Piloto , Humanos , Carcinoma de Células Escamosas/tratamiento farmacológico , Carcinoma de Células Escamosas/patología , Proliferación Celular/efectos de los fármacos , Ratones , Proteínas Proto-Oncogénicas c-bcl-2 , Apoptosis/efectos de los fármacos , Proteína X Asociada a bcl-2 , Modelos Animales de Enfermedad , Antígeno Ki-67 , Línea Celular Tumoral , Células HEK293 , Ensayos Antitumor por Modelo de Xenoinjerto , Ciclina B1 , Ratones Desnudos , XenoinjertosRESUMEN
The present study was designed to compare the effects of low-level laser with occlusal splints in patients with signs and symptoms of myofascial pain (MP) dysfunction syndrome. A total of 40 (34 women and 6 men, with a mean age of 32.84 [SD, 10.70] years) were selected after the diagnosis of MP according to the Research Diagnostic Criteria for Temporomandibular Disorder. The patients were randomly divided into 2 groups: study group (n = 20) and control group (n = 20). Low-level laser was applied to patients in the study group 2 times per week, for a total of 10 sessions. Patients in the control group were instructed to wear occlusal splints 24 h/d for 3 months. The functional examination was based on Research Diagnostic Criteria for Temporomandibular Disorder and pressure pain threshold values were obtained with the aid of an algometer in both groups. Patients' self-report of pain was evaluated with visual analog scale. Comparisons were made within and between the groups before and after treatment. Vertical movements showed statistically significant improvements after the treatments in both groups (P < 0.01), but when the groups were compared with each other, there were no significant difference between the groups. In both groups, tenderness to palpation of the muscles decreased significantly. Pressure pain threshold evaluations and visual analog scale scores revealed similar results, too. This particular type of low-level laser therapy (820 nm, 3 J/cm2, 300-mW output power) is as effective as occlusal splint in pain release and mandibular movement improvement in MP.
Asunto(s)
Terapia por Luz de Baja Intensidad/métodos , Ferulas Oclusales , Síndrome de la Disfunción de Articulación Temporomandibular/radioterapia , Adolescente , Adulto , Estudios de Casos y Controles , Dolor de Oído/radioterapia , Dolor de Oído/terapia , Dolor Facial/radioterapia , Dolor Facial/terapia , Femenino , Estudios de Seguimiento , Cefalea/radioterapia , Cefalea/terapia , Humanos , Láseres de Semiconductores/uso terapéutico , Masculino , Mandíbula/fisiopatología , Mandíbula/efectos de la radiación , Músculo Masetero/fisiopatología , Músculo Masetero/efectos de la radiación , Persona de Mediana Edad , Movimiento , Dimensión del Dolor , Umbral del Dolor , Rango del Movimiento Articular/fisiología , Autoinforme , Músculo Temporal/fisiopatología , Músculo Temporal/efectos de la radiación , Síndrome de la Disfunción de Articulación Temporomandibular/terapia , Adulto JovenRESUMEN
Maxillofacial prostheses are usually fabricated on the models obtained following the impression procedures. Disadvantages of conventional impression techniques used in production of facial prosthesis are deformation of soft tissues caused by impression material and disturbance of the patient due to. Additionally production of prosthesis by conventional methods takes longer time. Recently, rapid prototyping techniques have been developed for extraoral prosthesis in order to reduce these disadvantages of conventional methods. Rapid prototyping technique has the potential to simplify the procedure and decrease the laboratory work required. It eliminates the need for measurement impression procedures and preparation of wax model to be performed by prosthodontists themselves In the near future this technology will become a standard for fabricating maxillofacial prostheses.